Paxidep CR 25 is a generic, controlled-release formulation of paroxetine, a selective serotonin reuptake inhibitor (SSRI) extensively used in psychiatric treatment. This medication provides a stable and sustained increase in serotonin levels, which helps regulate mood and alleviate symptoms of depression, anxiety, and related disorders. Its controlled-release form supports improved adherence by reducing dosing frequency and minimizing peak-related side effects.

- Sleep & Mental Health > Depression, Anxiety, PTSD Paxidep CR 25 effectively treats major depressive disorder (MDD), generalized anxiety disorder (GAD), panic disorder, and post-traumatic stress disorder (PTSD) by promoting emotional balance and reducing excessive stress responses. > Obsessive-Compulsive Disorder (OCD) FDA-approved for OCD, it helps diminish compulsive behaviors and intrusive thoughts by enhancing serotonin neurotransmission, aiding patients in managing obsessive symptoms. > Panic Disorder Paxidep CR 25 is a key therapeutic option for panic disorder, reducing panic attack frequency and severity and helping prevent long-term relapse.

Paxidep CR 25 selectively inhibits serotonin reuptake transporters in the central nervous system, increasing synaptic serotonin concentration. This action restores chemical balance in the brain, improving mood, lowering anxiety levels, and providing symptom relief for multiple psychiatric conditions.

Adult Dosing - Depression & Major Depressive Disorder (MDD): IR: Start 20 mg daily; Maintenance 20–50 mg; Max 50 mg CR: Start 25 mg daily; Maintenance 25–62.5 mg; Max 62.5 mg Dose increments weekly by 10 mg (IR) or 12.5 mg (CR). Treatment duration typically spans several months with demonstrated efficacy up to one year. - Social Anxiety Disorder (SAD): IR: Start 20 mg daily; Maintenance 20–60 mg; Max 60 mg CR: Start 12.5 mg daily; Maintenance 12.5–37.5 mg; Max 37.5 mg Treatment lasts up to 12 weeks with weekly dose adjustments based on response. - Panic Disorder (PD): IR: Start 10 mg daily; Maintenance 10–40 mg; Max 60 mg CR: Start 12.5 mg daily; Maintenance 12.5–75 mg; Max 75 mg Treatment duration up to 12 weeks with weekly dose escalations. - Premenstrual Dysphoric Disorder (PMDD): CR formulation only; continuous dosing 12.5–25 mg daily or cyclic administration beginning 14 days before menstruation. Effective for at least 3 menstrual cycles with possibility for dose adjustment. - Obsessive Compulsive Disorder (OCD): IR: Start 20 mg daily; Maintenance 20–60 mg; Max 60 mg Requires chronic treatment with weekly dose increases of 10 mg. - Post-Traumatic Stress Disorder (PTSD) & Generalized Anxiety Disorder (GAD): IR: Start 20 mg daily; Maintenance 20–50 mg; Max 50 mg Treatment period extends up to 12 weeks with weekly dose increases. - Postmenopausal Symptoms: Mesylate capsules 7.5 mg daily, indicated specifically for vasomotor symptoms. Geriatric Dosing - Start at lower doses (around 10 mg daily) with maintenance doses up to 40 mg daily for depression, OCD, PTSD, SAD, GAD, and PD. - Weekly dose increases are advised depending on tolerability. - Not recommended for mild, transient anxiety associated with routine stressors.

Store Paxidep CR 25 tablets in a cool, dry environment away from direct sunlight and humidity. Maintain the medication in its original packaging to protect from moisture and keep out of reach of children and pets. Proper storage preserves the drug’s effectiveness and safety throughout its shelf life.

Common side effects include nausea, dizziness, headache, drowsiness, dry mouth, sexual dysfunction, and gastrointestinal disturbances such as constipation or diarrhea. Less common but serious adverse effects include serotonin syndrome, increased bleeding risk, and withdrawal symptoms if discontinued abruptly. Monitoring and consultation with healthcare providers are essential for safe use.